First-Line Treatment for Amyopathic Dermatomyositis

Initial Treatment Approach

The American College of Physicians recommends starting hydroxychloroquine at 200 mg twice daily (5 mg/kg/day) as first-line monotherapy for patients with amyopathic dermatomyositis who have cutaneous manifestations without muscle weakness 1
Baseline ophthalmologic examination is mandatory before initiating hydroxychloroquine, with annual screening beginning within 5 years if risk factors for retinal toxicity exist, as recommended by the Mayo Clinic 1
Rigorous sun protection with SPF 50+ sunscreen and physical barriers is paramount to prevent photosensitive rash exacerbations, according to the Annals of the Rheumatic Diseases 1, 2
Topical corticosteroids or topical tacrolimus 0.1% can be used for localized symptomatic skin disease, as suggested by the Mayo Clinic Proceedings and the Annals of the Rheumatic Diseases 1, 2

Evaluate treatment response at 12 weeks to determine if escalation is needed, as recommended by Praxis Medical Insights 3
Add oral prednisone 0.5-1 mg/kg/day combined with methotrexate 15-20 mg/m² weekly for patients who fail hydroxychloroquine monotherapy, according to Praxis Medical Insights 3, 4
Intravenous immunoglobulin (IVIG) 1-2 g/kg over 2 consecutive days is particularly effective for refractory cutaneous disease, as reported in the Mayo Clinic Proceedings 5
Mycophenolate mofetil starting at 500 mg twice daily is useful for severe skin disease and can be used as an alternative to methotrexate, as suggested by Praxis Medical Insights 4, 6
Baseline electrocardiogram to screen for QT prolongation before hydroxychloroquine initiation is recommended by the Mayo Clinic Proceedings 1
Ophthalmologic monitoring using multifocal electroretinography and spectral domain optical coherence tomography is necessary, as recommended by the Mayo Clinic Proceedings 1
Complete blood count and liver function tests are required if escalating to methotrexate or mycophenolate mofetil, according to Praxis Medical Insights 6

Do not overlook the need for systemic immunosuppression, as ongoing skin disease reflects ongoing systemic disease and should be treated with increased systemic therapy, not just topical agents, as recommended by the Annals of the Rheumatic Diseases 2